Mankind Pharma Ltd Share Price

2,581.8
(4.04%)
Feb 3, 2025|03:31:37 PM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Equities

Futures

Option

  • Open2,445
  • Day's High2,595
  • 52 Wk High3,054.8
  • Prev. Close2,481.6
  • Day's Low2,434.8
  • 52 Wk Low 1,901.05
  • Turnover (lac)11,594.63
  • P/E52.93
  • Face Value1
  • Book Value343.9
  • EPS46.87
  • Mkt. Cap (Cr.)1,06,516.52
  • Div. Yield0
View All Historical Data
No Records Found

Mankind Pharma Ltd KEY RATIOS

Sector

Pharmaceuticals

Open

2,445

Prev. Close

2,481.6

Turnover(Lac.)

11,594.63

Day's High

2,595

Day's Low

2,434.8

52 Week's High

3,054.8

52 Week's Low

1,901.05

Book Value

343.9

Face Value

1

Mkt Cap (₹ Cr.)

1,06,516.52

P/E

52.93

EPS

46.87

Divi. Yield

0

Mankind Pharma Ltd Corporate Action

13 Jan 2025

12:00 AM

Board Meeting

Agenda : Audited Result

arrow

18 Jul 2024

12:00 AM

AGM

Announcement Date: 18 Jul, 2024

arrow

Mankind Pharma Ltd NEWS AND UPDATE

Top Stocks for Today - 24th January 2025
24 Jan 2025|07:50 AM

Here are some of the stocks that may see significant price movement today: Indus Towers, Dr Reddy’s Laboratories, Mankind Pharma, etc.

Read More
Mankind Pharma Q3 Profit Falls 16%, Revenue Jumps 24%
23 Jan 2025|11:57 PM

The company reported a good growth in EBITDA of 36.8% to ₹830 crore in the quarter against ₹606.5 crore in Q3 FY24.

Read More
Mankind Pharma Secures ₹5,000 Crore NCDs by Pledging 56.31% Stake in BSV
8 Jan 2025|04:01 PM

The NCDs issued are categorized, rated, secured, redeemable, and transferable, distributed across three series.

Read More
Mankind Pharma, Innovent Join Forces for Cancer Care
26 Dec 2024|12:46 PM

According to the National Cancer Registry Programme, cancer is expected to cause 29.8 million DALYs by 2025, making it a serious health issue in India.

Read More
Mankind Pharma Secures ₹3,000 Crore via QIP for Growth
20 Dec 2024|02:06 PM

The issue price includes a premium of ₹2,519 per share, aggregating a total of ₹2,999.99 crore.

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Mankind Pharma Ltd SHAREHOLDING SNAPSHOT

03 Feb, 2025|04:37 PM
  • Foreign Promoter
  • Indian Promoter
  • Institutions
  • Non Institutions
  • Custodies

Promoter- 72.70%

Foreign: 0.00%

Indian: 72.70%

Non-Promoter- 24.37%

Institutions: 24.37%

Non-Institutions: 2.92%

Custodian: 0.00%

Share Price

Mankind Pharma Ltd FINANCIALS

Balance Sheet

Profit & Loss

Cash Flow

Ratios

Results

Y/e 31 Mar( In .Cr)Mar-2024Mar-2023Mar-2022Mar-2021

Equity Capital

40.06

40.06

40.06

40.06

Preference Capital

0

0

0

0

Reserves

9,583.75

7,743.85

6,500.39

4,694.21

Net Worth

9,623.81

7,783.91

6,540.45

4,734.27

Minority Interest

View Balance Sheet

No Record Found

View Profit & Loss

No Record Found

View Cash Flow

No Record Found

View Ratios
Particulars (Rupees in Crores.)Mar-2024Mar-2023Mar-2022Mar-2021Mar-2020

Gross Sales

10,334.77

8,749.43

7,781.56

6,214.43

5,865.23

Excise Duty

0

0

0

0

0

Net Sales

10,334.77

8,749.43

7,781.56

6,214.43

5,865.23

Other Operating Income

0

0

0

0

0

Other Income

296.07

140.99

210.48

182.63

121.96

Mankind Pharma Ltd Peer Comparison

Company Name
LTP
(₹)
P/E
(%)
Mkt.Cap
(₹Cr.)
NP Qtr
(₹Cr.)
Div.Yield
(%)
Sales Qtr
(₹.Cr)
Book Value
(₹)

Sun Pharmaceuticals Industries Ltd

SUNPHARMA

1,742.2

151.674,18,132.111,181.050.775,985.3398.33

Divis Laboratories Ltd

DIVISLAB

5,618.55

81.251,49,254.45180.532,302513.62

Cipla Ltd

CIPLA

1,439.5

24.951,16,122.781,438.150.94,134.87360.73

Torrent Pharmaceuticals Ltd

TORNTPHARM

3,207.7

59.461,08,471.974850.872,330222.38

Mankind Pharma Ltd

MANKIND

2,481.6

52.931,02,347.53416.3802,396.57334.18

Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.

MORE ABOUT Mankind Pharma Ltd

Management

Register Office

Registrar Office

Chairman & Wholetime Director

RAMESH CHAND JUNEJA

Vice Chairman & M.D.

RAJEEV JUNEJA

Whole Time Director & CEO

SHEETAL ARORA

Independent Director

TILOKCHAND PUNAMCHAND OSTWAL

Independent Director

Bharat Anand

Whole-time Director

SATISH KUMAR SHARMA

Independent Director

Vivek Kalra

Independent Director

Vijaya Sampath

Company Sec. & Compli. Officer

Hitesh Kumar Jain

Registered Office


Tel: -

Website: -

Email: -

Registrar Office


Tel: -

Website: -

Email: -

Summary

Mankind Pharma Limited was incorporated on July 3, 1991, as a Private Limited Company with the name Mankind Pharma Private Limited, by the Registrar of Companies, Delhi and Haryana, at New Delhi. Pursuant to conversion of Company to a Public Limited dated July 14, 2005, name of the Company was changed to Mankind Pharma Limited and the RoC issued a fresh Certificate of Incorporation on April 13, 2006.The Company is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations and chronic therapeutic areas across, as well as several consumer healthcare products. It is present in several acute and chronic therapeutic areas in India, including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins /minerals / nutrients and respiratory. In 2004, the Company entered the chronic pharmaceutical segment with the launch of Amlokind tablets and Glimestar tablets amongst others. It set up their first manufacturing facility at Paonta Sahib, in Himachal Pradesh during year 2005. It entered the ophthalmic pharmaceutical segment with the launching of Lubistar Eye Drops and Tobastar Eye Drops. In 2007, the Company entered the consumer healthcare segment with the launch of Manforce brand and have since established several differentiated brands in condoms, pregnancy detection, emergency contraceptives, antacid powders, vitamin and mineralsupplements and anti-acne preparations categories. It entered into the business of animal h
Read More

Company FAQs

What is the Mankind Pharma Ltd share price today?

The Mankind Pharma Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹2581.8 today.

What is the Market Cap of Mankind Pharma Ltd?

Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Mankind Pharma Ltd is ₹106516.52 Cr. as of 03 Feb ‘25

What is the PE and PB ratio of Mankind Pharma Ltd?

The PE and PB ratios of Mankind Pharma Ltd is 52.93 and 7.42 as of 03 Feb ‘25

What is the 52 Week High and Low of Mankind Pharma Ltd?

The 52-week high/low is the highest and lowest price at which a Mankind Pharma Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Mankind Pharma Ltd is ₹1901.05 and ₹3054.8 as of 03 Feb ‘25

What is the CAGR of Mankind Pharma Ltd?

Mankind Pharma Ltd's CAGR for 5 Years at N/I%, 3 Years at N/I%, 1 Year at 21.28%, 6 Month at 23.79%, 3 Month at -7.43% and 1 Month at -13.86%.

What is the shareholding pattern of Mankind Pharma Ltd?

The shareholding pattern of Mankind Pharma Ltd is as follows:
Promoters - 72.71 %
Institutions - 24.40 %
Public - 2.90 %

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.